Corit Medical positions for commercial scale and strategic exit as Series A nears completion

Following its participation in the ACA Summit Innovation Funders Showcase, Corit Medical is building momentum as it advances commercial execution, engages new investors, and sharpens its focus on a short-term strategic exit.

Corit is advancing a differentiated approach to turbinate reduction with a single-use device designed to simplify treatment for nasal airway obstruction while preserving established surgical principles and reimbursement pathways. Unlike many early-stage medtech companies, Corit enters this next phase with key value inflection points already in place, including FDA registration, established reimbursement, protected intellectual property, and real-world clinical use.

With more than 300 procedures completed and no reported device-related adverse events, the company is moving beyond foundational development and into disciplined commercial activation. Corit has established manufacturing infrastructure and is advancing a controlled commercial pilot designed to validate adoption and support broader distributor engagement.

As part of this next growth phase, Corit is working to close the final $1 million in its Series A financing. The capital is intended to support commercial acceleration, revenue validation, and strategic milestones aligned with the company’s acquisition pathway.

“A number of medtech companies spend years overcoming reimbursement, regulatory, and supply chain hurdles,” said Aaron Tutwiler, CEO of Corit Medical. “We have moved through those barriers and are now focused on commercial execution, value creation, and positioning the business for strategic acquisition opportunities. Our goal is to build intelligently, prove market adoption, and create value in a way that aligns with both patients and potential acquirers.”

Recent strategic activity in the ENT sector continues to support interest in technologies that improve procedural efficiency while fitting into established care pathways. Corit believes this environment creates a compelling backdrop for focused execution and disciplined growth.

The company will continue investor engagement at the upcoming MedTech World Conference, taking place May 11 to 13 in West Palm Beach, Florida, where management plans to meet with investors, strategic partners, and industry stakeholders as it advances both financing and commercialization initiatives.

As Corit enters this next chapter, the company remains focused on a clear objective: convert operational readiness into commercial traction, and commercial traction into strategic value.

Investors, partners, and attendees interested in connecting with Corit during MedTech World North America 2026 are invited to engage with the management team during the conference.

Join the conversation at MedTech World North America 2026

Be part of MedTech World North America 2026, taking place May 11–13, and connect with the people building and backing the next wave of MedTech companies.

Explore the agenda and book your ticket now to avoid the last-minute rush.